Adzynma® (ADAMTS13, Recombinant-krhn) - CAM 959HB

Background

FDA Approved Indication: Adzynma is a recombinant ADAMTS13 enzyme replacement therapy indicated for prophylactic and on-demand treatment in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). It is the first FDA-approved recombinant ADAMTS13 product designed to replace the deficient enzyme responsible for the disease.

Policy

Initial Authorization Criteria

Adzynma may be considered medically necessary when all of the following criteria are met:

  1. Diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP)
  1. Molecular genetic testing confirms pathogenic mutation(s) in the ADAMTS13 gene
  1. Trial and inadequate response, contraindication, or intolerance to plasma-based infusions (e.g., fresh frozen plasma [FFP] or plasma infusion therapy)

Authorization Duration: 6 months

Reauthorization Criteria

Adzynma may be reauthorized when all of the following criteria are met:

  1. Patients demonstrate a positive clinical response to therapy, evidenced by one or more of the following:
    • Reduction or prevention of acute TTP episodes;
    • Improvement or stabilization of platelet counts;
    • Improvement in hemolytic markers (e.g., LDH, hemoglobin, schistocyte burden);
    • Reduction in the need for plasma-based treatments, hospitalizations, or emergency interventions;
    • Physician documentation of clinical benefit.
  1. Continued inadequate response, contraindication, or intolerance to plasma-based infusions

Reauthorization Duration: 12 months

References

  1. ADZYNMA (ADAMTS13, recombinant-krhn) Prescribing Information. Takeda Pharmaceuticals U.S.A., Inc.; revised 2026. [content.takeda.com], [fda.gov]
  2. U.S. Food and Drug Administration (FDA). Package Insert and Patient Information: ADZYNMA. November 2023. [fda.gov], [fda.gov]
  3. U.S. Food and Drug Administration (FDA). FDA Takes Action on New Boxed Warning for Adzynma Enzyme Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura. September 23, 2026. [fda.gov]
  4. Takeda Pharmaceuticals. ADZYNMA Healthcare Professional Information. [adzynma.com]
  5. Takeda Pharmaceuticals. Takeda's ADZYNMA Approved by FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for cTTP. November 9, 2023. [takeda.com]
  6. International Society on Thrombosis and Haemostasis (ISTH). Current understanding and management principles of congenital thrombotic thrombocytopenic purpura.
  7. Adzynma Prescribing Information, updated boxed warning and safety information. [takeda.com], [drugs.com]

Coding Section

Code

Number

Description

ICD-10

M31.19

Other thrombotic microangiopathy

 

D69.42

Congenital and hereditary thrombocytopenia purpura

CPT

96374

Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug

HCPCS

J7171

Injection, ADAMTS13, recombinant-krhn, 10 IU

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2026 Forward

10/01/2026

New Policy

Complementary Content
${loading}